These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26255866)

  • 21. Uropathogenic Escherichia coli mediated urinary tract infection.
    Totsika M; Moriel DG; Idris A; Rogers BA; Wurpel DJ; Phan MD; Paterson DL; Schembri MA
    Curr Drug Targets; 2012 Oct; 13(11):1386-99. PubMed ID: 22664092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanodiamonds facilitate killing of intracellular uropathogenic E. coli in an in vitro model of urinary tract infection pathogenesis.
    Iyer JK; Dickey A; Rouhani P; Kaul A; Govindaraju N; Singh RN; Kaul R
    PLoS One; 2018; 13(1):e0191020. PubMed ID: 29324795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
    Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Features of uropathogenic Escherichia coli able to invade a prostate cell line.
    Longhi C; Comanducci A; Riccioli A; Ziparo E; Marazzato M; Aleandri M; Conte AL; Lepanto MS; Goldoni P; Conte MP
    New Microbiol; 2016 Apr; 39(2):146-9. PubMed ID: 27196555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct isolates of uropathogenic Escherichia coli differentially affect human sperm parameters in vitro.
    Boguen R; Uribe P; Treulen F; Villegas JV
    Andrologia; 2014 Oct; 46(8):943-7. PubMed ID: 24079260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A flow cytometry-based assay for screening FimH antagonists.
    Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B
    Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
    Habibi M; Asadi Karam MR; Bouzari S
    Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview.
    Mittal R; Aggarwal S; Sharma S; Chhibber S; Harjai K
    J Infect Public Health; 2009; 2(3):101-11. PubMed ID: 20701869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli.
    Billips BK; Forrestal SG; Rycyk MT; Johnson JR; Klumpp DJ; Schaeffer AJ
    Infect Immun; 2007 Nov; 75(11):5353-60. PubMed ID: 17724068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escherichia coli mediated urinary tract infections: are there distinct uropathogenic E. coli (UPEC) pathotypes?
    Marrs CF; Zhang L; Foxman B
    FEMS Microbiol Lett; 2005 Nov; 252(2):183-90. PubMed ID: 16165319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
    Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
    Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract.
    Lane MC; Lockatell V; Monterosso G; Lamphier D; Weinert J; Hebel JR; Johnson DE; Mobley HL
    Infect Immun; 2005 Nov; 73(11):7644-56. PubMed ID: 16239569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Host-pathogen interactions in urinary tract infection.
    Nielubowicz GR; Mobley HL
    Nat Rev Urol; 2010 Aug; 7(8):430-41. PubMed ID: 20647992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle.
    Alteri CJ; Smith SN; Mobley HL
    PLoS Pathog; 2009 May; 5(5):e1000448. PubMed ID: 19478872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The unexplored relationship between urinary tract infections and the autonomic nervous system.
    Hibbing ME; Conover MS; Hultgren SJ
    Auton Neurosci; 2016 Oct; 200():29-34. PubMed ID: 26108548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation.
    Garofalo CK; Hooton TM; Martin SM; Stamm WE; Palermo JJ; Gordon JI; Hultgren SJ
    Infect Immun; 2007 Jan; 75(1):52-60. PubMed ID: 17074856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination approaches for the prevention of urinary tract infection.
    Moriel DG; Schembri MA
    Curr Pharm Biotechnol; 2013; 14(11):967-74. PubMed ID: 24372245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nature of immune responses to urinary tract infections.
    Abraham SN; Miao Y
    Nat Rev Immunol; 2015 Oct; 15(10):655-63. PubMed ID: 26388331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary tract infection of mice to model human disease: Practicalities, implications and limitations.
    Carey AJ; Tan CK; Ipe DS; Sullivan MJ; Cripps AW; Schembri MA; Ulett GC
    Crit Rev Microbiol; 2016 Sep; 42(5):780-99. PubMed ID: 26006172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasion of Host Cells and Tissues by Uropathogenic Bacteria.
    Lewis AJ; Richards AC; Mulvey MA
    Microbiol Spectr; 2016 Dec; 4(6):. PubMed ID: 28087946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.